Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab

Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute discusses Scientific Rational for 2 month lead-in of Idelalisib Prior to Initiation of Ofatumumab in CL... Author: ASHReport Added: 12/10/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts